An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide.

TPS334 Background: Doxorubicin and ifosfamide are active in the treatment of sarcomas; however, this regimen is associated with grade 3/4 chemotherapy-induced thrombocytopenia (CIT), which may necessitate chemotherapy dose reductions and dose delays with the consequence of less disease control. Thrombocytopenia can also increase the risk of hemorrhage. CIT is primarily managed with dose reductions, dose delays, and platelet transfusions, each of which has significant limitations. Eltrombopag, an oral, small molecule thrombopoietin receptor agonist, increases platelet counts in patients with chronic immune thrombocytopenic purpura, chronic liver disease, and hepatitis C infection. This study will evaluate the safety and effectiveness of eltrombopag in patients with cancer. Methods: This open- label, nonrandomized, phase I, 2-part, sequential cohort, dose-escalation study will evaluate the safety and efficacy of eltrombopag when administered to patients receiving doxorubicin/ifosfamide. Eligible adult patie...